Parameter
| Biomarker | CXCL13 | Full name | Chemokine (C-X-C motif) ligand 13 (B cell-attracting chemokine 1) | Molecular Type | Chemokines |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and treatment resistance | ||
| Disease | Colorectal Cancer (CRC) | Disease Subtypes | / | ||
| Organ | Colorectal | Test Sample / Technology Platform | Tumor tissue/blood (ELISA, qRT-PCR) | ||
| Pathobiological Mechanisms | Binding CXCR5 to recruit B cells to form tertiary lymphoid structures and activate PI3K/AKT pathway to promote tumor progression, which is related to 5-FU resistance | ||||
| Clinical Availability Status | Research validation: serum levels are associated with CRC drug resistance, which is in the early clinical research stage | ||||
| Notes and Dynamics | The serum level of CXCL13 can predict the sensitivity of CRC patients to 5-FU chemotherapy, and targeting CXCL13/CXCR5 axis is expected to reverse chemotherapy resistance | ||||